MD&M West 2018


6 - 8 Feb 2018
Anaheim Convention Center | Anaheim, CA
mdmwest.mddionline.com

Clariant MEVOPUR® and REMAFIN-EP® Ingredients Fully Comply With 2020 USP<661.1> Requirements

ClariantMuttenz, February 6, 2018 – Clariant, a world leader in specialty chemicals, announces completion of testing on ingredients in its MEVOPUR and REMAFIN-EP product ranges in order to bring them into full compliance with USP <661.1>. The new standard for pharmaceutical packaging and drug delivery devices doesn’t take effect until May 2020, when it will impact all current and future drugs on the U.S. market. Clariant is completing the testing process now to help customers “future-proof” packaging launched in the interim and, in addition, to offer data to support the ICH-Q3D guidelines for risk assessment of elemental impurities in drugs.

Clariant Offers ‘Future-Proofing’ for Next-Gen Drug Packaging, Delivery Devices at MD&M 2018

Clariant Offers ‘Future-Proofing’ for Next-Gen Drug Packaging, Delivery Devices at MD&M 2018. 
(Photos: Clariant)Muttenz, December 14, 2017 – Clariant, a world leader in specialty chemicals, will share how its MEVOPUR® and REMAFIN-EP® products can help in ‘future-proofing’ pharmaceutical packaging and drug-delivery devices in advance of new USP<661.1> regulations at the upcoming MD&M West exhibition. Experts from Clariant’s Healthcare Polymer Solutions will be on hand in Booth 2049 at the medical device trade show being held from Feb. 6-8 at the Anaheim Convention Center, Anaheim CA.